Aspira Women's Health Inc. (AWHL): Revenue

Annual figures by period end, from SEC filings.

$9.22M

Year ended 2025-12-31

$8.55M

Trailing 12 months to 2026-06-30

2023-12-31 Revenue (USD) 2025-12-31

Period ended	Revenue	Change YoY	Source filing
2025-12-31	$9.22M	+0.4%	2026-04-01, From 2025-01-01
2024-12-31	$9.18M	+0.3%	2026-04-01, From 2024-01-01
2023-12-31	$9.15M	n/a	2025-03-27, From 2023-01-01

Revenue at similar companies

Companies with the same SEC industry code (In Vitro & In Vivo Diagnostic Substances), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

Company	Year ended	Revenue	Change YoY
Aspira Women's Health Inc. (AWHL)	2025-12-31	$9.22M	+0.4%
Anbio Biotechnology (NNNN)	2025-12-31	$8.65M	+5.6%
Biomerica Inc (BMRA)	2026-05-31	$4.45M	-16.2%
Insight Molecular Diagnostics Inc. (IMDX)	2025-12-31	$4.05M	+115.6%
Immucell Corp (ICCC)	2025-12-31	$27.64M	+4.3%
Alpha Teknova, Inc. (TKNO)	2025-12-31	$40.52M	+7.4%
Volitionrx Ltd (VNRX)	2025-12-31	$1.73M	+40.0%
Celldex Therapeutics, Inc. (CLDX)	2025-12-31	$1.54M	-78.0%
Intellia Therapeutics, Inc. (NTLA)	2025-12-31	$67.67M	+16.9%

Compare AWHL, NNNN, BMRA, IMDX side by side · Screen every company in In Vitro & In Vivo Diagnostic Substances ↗